MedPath

Comparison of low dose midazolam and etomidate for the Prevention of myoclonic Movements following etomidate Injection.

Phase 3
Conditions
Myoclonic Movements.
Registration Number
IRCT20160307026950N6
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
120
Inclusion Criteria

All Patients candidate Electroconvulsive Therapy
ASA I,ASAII
Age 6 - 15 years

Exclusion Criteria

Severe cardiovascular disease
kidney disease
Liver disease
Chronic respiratory disease
drugs Allergy
discontinue of cooperation
intubation

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath